Development of a design research for determining the quality indicators of potential API. 1. newly synthesized substances for primary pharmacological screening




Active substance, standardization, quality requirements, research design, analysis methods


The constant growth in the world of medicinal products of synthetic origin determines the search, directed synthesis and pharmacological studies of new biologically active substances. The establishment of the structure of the substance and the study of physical and chemical properties requires the use of a number of methods and tests that allow obtaining a substance with "pharmacopoeial quality" already at the stage of synthesis of potential API. Changes in the further conditions of synthesis, solvents for crystallization, etc. can lead to a change in the profile of impurities and their quantity, obtaining other polymorphic modifications, isomers, etc. and as a result - to a change in the pharmacological properties. To prevent this, the requirements for substances that are transferred for pharmacological screening must be unified.

Objective: The purpose of the work is to summarize the information of methods of establishing the structure and physico-chemical properties of new biologically active substances, assess their compliance with pharmacopoeial quality requirements and formulate mandatory requirements for standardization of first synthesized substances for their transfer for primary pharmacological screening in the form of the structure of the primary "certificate of quality".

Materials and methods. The research uses the collection and analysis of data from modern scientific literature and regulatory documents.

Results. The conformity of research on the structure of the first synthesized substances to pharmacopoeial quality indicators of substances has been determined, the structure of "certificate of their quality" has been proposed, the basic principles of ensuring stable quality indicators in the synthesis of API have been highlighted.

Discussion. The obligatory definition for the newly synthesized substances such indicators as melting point, solubility in solvents of different polarity (lipofilicity), elemental composition and / or molecular weight is justified. From physical and chemical methods, UV, IR, and at least PMR spectroscopy are mandatory, the use of at least one of the chromatographic methods - TLC with the use of witness substances, or LC/MS (preferred, because in addition to purity allows to estimate the quantitative content of matter and the profile of impurities) is mandatory.

Conclusions. Approaches to the peculiarities of establishing the structure and studying the properties of a newly synthesized substance with the promising biological activity using physical, physico-chemical and chemical methods are generalized. The methods of establishing the BAS structure are unified, which fully characterize the structure, provide information on the purity and quantity of the compound at the initial stage of pharmacological tests. The main principles of ensuring stable quality indicators in the synthesis of potential API are highlighted

Author Biographies

Nataliia Bevz, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002

PhD, Associate Professor

Department of Pharmaceutical Chemistry

Volodymyr Mishchenko, Institute for Advanced Training of Pharmacy Specialists National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002

Associate professor

Department of quality, standardization and certification of medicines


  1. Carey, J. S., Laffan, D.; Blacker, J., Williams, M. T. (Eds.) (2011). Active Pharmaceutical Ingredients: Structure and Impact on Synthesis. Pharmaceutical Process Development: Current Chemical and Engineering Challenges, 39–65. doi:
  2. Honda, T. (2012). Investigation of Innovative Synthesis of Biologically Active Compounds on the Basis of Newly Developed Reactions. Chemical and Pharmaceutical Bulletin, 60 (6), 687–705. doi:
  3. Zhong, W.-Z., Zhou, S.-F. (2014). Molecular Science for Drug Development and Biomedicine. International Journal of Molecular Sciences, 15 (11), 20072–20078. doi:
  4. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9, 203–214. doi:
  5. Zhou, S.-F., Zhong, W.-Z. (2017). Drug Design and Discovery: Principles and Applications. Molecules, 22 (2), 279. doi:
  6. Adams, C. P., Brantner, V. V. (2003). New Drug Development: Estimating entry from human clinical trials. Bureau of Economics Federal Trade Commission, 24.
  7. Elhassa, G. O., Alfarouk, K. O. (2015). Drug Development: Stages of Drug Development. Journal of Pharmacovigilance, 3 (3). doi:
  8. The Pharmaceutical Industry in Figures (2019). Key Data. Available at:
  9. Jackson, C. M., Esnouf, M. P., Winzor, D. J., Duewer, D. L. (2007). Defining and measuring biological activity: applying the principles of metrology. Accreditation and Quality Assurance, 12 (6), 283–294. doi:
  10. National Research Council (US) Committee on Challenges for the Chemical Sciences in the 21st Century. Beyond the Molecular Frontier: Challenges for Chemistry and Chemical Engineering (2003). Washington (DC): National Academies Press (US), 3, Synthesis and Manufacturing: Creating and Exploiting New Substances and New Transformations. Available at:
  11. Taylor, D. (2015). The Pharmaceutical Industry and the Future of Drug Development. Pharmaceuticals in the Environment, 1–33.
  12. Directive 75/318/EEC Chemistry of Active Substances. 1987. Available at:
  13. Rama Rao, N., Mani Kiran, S. S., Prasanthi, N. L. (2010). Pharmaceutical Impurities: An Overview. Indian Journal of Pharmaceutical Education and Research, 44 (3), 301–310.
  14. Cok, I., Emerce, E. (2012). Overview of impurities in pharmaceuticals: Toxicological aspects. Asian Chemistry Letters, 16 (1), 87–97.
  15. ICH Harmonized Tripartite Guideline: Q3A (R2) Impurities in New Substances (2006). The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 15.
  16. Galloway, W. R. J. D., Isidro-Llobet, A., Spring, D. R. (2010). Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nature Communications, 1 (1). doi:
  17. Chandrawanshi, H., Pilaniya, U., Manchandani, P., Jain, P., Singh, N., Pilaniya, K. (2010). Recent trends in the impurity profile of pharmaceuticals. Journal of Advanced Pharmaceutical Technology & Research, 1 (3), 302–310. doi:
  18. Kelce, W. R., Castle, K. E., Ndikum-Moffor, F. M., Patton, L. M. (2017). Drug substance and drug product impurities, now what? MOJ Toxicology, 3 (1), 9–13. doi:
  19. McDonald, K., Ho, K. (2012). ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities. Generics and Biosimilars Initiative Journal, 1 (3-4), 142–144. doi:
  20. Derzhavna Farmakopeia Ukrainy. T. 1 (2015). Kharkiv: Derzhavne pidpryiemstvo «Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv», 1128.
  21. The European Pharmacopoeia (2018). European Directorate for the Quality of Medicines & HealthCare of the Council of Europe. Vol. 6. Strasbourg. Available at:
  22. The United States Pharmacopoeia, 41–NF 36 (2018). The United States Pharmacopeial Convention. Rockville. Available at:
  23. EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev. 1. Guideline on process validation for finished products – information and data to be provided in regulatory submissions (2014). Available at:
  24. Liapunov, M., Bezuhla, O., Soloviov, O. et. at. (2012). Standartyzatsiia farmatsevtychnoi produktsii. Kharkiv: Morion, 728.
  25. Vetiutneva, N. O., Ubohov, S. H., Pylypchuk, L. B., Fedorova, L. O., Todorova, V. I., Budnikova, T. M. et. at. (2014). Suchasnyi stan ta tendentsii rozvytku normatyvno-pravovoho rehuliuvannia u sferi zabezpechennia yakosti likarskykh zasobiv. Farmatsevtychnyi zhurnal, 3, 66–74.
  26. Ghislieri, D., Gilmore, K., Seeberge, P. H. (2015). Chemical Assembly Systems: Layered Control for Divergent, Continuous, Multistep Syntheses of Active Pharmaceutical Ingredients. Angewandte International Edition Chemie, 54 (2), 678–682. doi:
  27. Ukrainets, I., Burian, A., Baumer, V., Shishkina, S., Sidorenko, L., Tugaibei, I. et. al. (2018). Synthesis, Crystal Structure, and Biological Activity of Ethyl 4-Methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxylate Polymorphic Forms. Scientia Pharmaceutica, 86 (2), 21. doi:
  28. Ukrainets, I., Hamza, G., Burian, A., Voloshchuk, N., Malchenko, O., Shishkina, S. et. al. (2018). Molecular Conformations and Biological Activity of N-Hetaryl(aryl)alkyl-4-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamides. Scientia Pharmaceutica, 86 (4), 50. doi:
  29. Yamano, A. (2013). Special Feature: Pharmaceutical Analysis (2). Drug discovery by single crystal X-ray structure analysis. Rigaku Journal, 29 (2), 4–7.
  30. Marion, D. (2013). An Introduction to Biological NMR Spectroscopy. Molecular & Cellular Proteomics, 12 (11), 3006–3025. doi:
  31. Pellecchia, M., Sem, D. S., Wüthrich, K. (2002). Nmr in drug discovery. Nature Reviews Drug Discovery, 1 (3), 211–219. doi:
  32. Berger, S., Braun, S. (Eds.) (2004). 200 and More NMR Experiments: A Practical Course. Weinheim, 838.
  33. Shirazi, Z., Kargosha, K. (2015). Determination of Water Content of Crystalline Pharmaceutical Solids under Different Percentages of Relative Humidity. Pharmaceutical Sciences, 21 (3), 127–135. doi:
  34. Holm, R., Elder, D. P. (2016). Analytical advances in pharmaceutical impurity profiling. European Journal of Pharmaceutical Sciences, 87, 118–135. doi:
  35. Sneddon, J., Masuram, S., Richert, J. C. (2007). Gas Chromatography‐Mass Spectrometry‐Basic Principles, Instrumentation and Selected Applications for Detection of Organic Compounds. Analytical Letters, 40 (6), 1003–1012. doi:
  36. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials (2007). Vol. 2. Second updated edition. Geneva: World Health Organization. Good manufacturing practices and inspection, 46.
  37. Vogt, F. G., Kord, A. S. (2011). Development of Quality-By-Design Analytical Methods. Journal of Pharmaceutical Sciences, 100 (3), 797–812. doi:




How to Cite

Bevz, N., & Mishchenko, V. (2019). Development of a design research for determining the quality indicators of potential API. 1. newly synthesized substances for primary pharmacological screening. ScienceRise: Pharmaceutical Science, (5 (21), 18–26.



Pharmaceutical Science